Ubs Group Ag Io Biotech, Inc. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IOBT
# of Institutions
19Shares Held
23.6MCall Options Held
0Put Options Held
0-
Vivo Capital, LLC Palo Alto, CA6.17MShares$5.31 Million0.95% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA3.64MShares$3.13 Million2.22% of portfolio
-
Novo Holdings Hellerup, G73.35MShares$2.88 Million0.25% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA2.34MShares$2.01 Million0.14% of portfolio
-
Morgan Stanley New York, NY2.2MShares$1.89 Million0.0% of portfolio
About IO Biotech, Inc.
- Ticker IOBT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,815,300
- Market Cap $24.8M
- Description
- IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in ph...